Aurinia Pharmaceuticals (AUPH) Competitors

$16.40 -0.27 (-1.62%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$16.40 0.00 (0.00%)

As of 04:00 AM Eastern

AUPH vs. IBRX, TGTX, PCVX, CYTK, and APGE

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? Aurinia Pharmaceuticals's main competitors and comparable companies include ImmunityBio (IBRX), TG Therapeutics (TGTX), Vaxcyte (PCVX), Cytokinetics (CYTK), and Apogee Therapeutics (APGE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aurinia Pharmaceuticals compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

ImmunityBio has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to ImmunityBio's net margin of -598.55%. Aurinia Pharmaceuticals' return on equity of 26.11% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

In the previous week, ImmunityBio had 6 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 6 mentions for ImmunityBio and 0 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.57 beat ImmunityBio's score of 0.54 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmunityBio	Positive
Aurinia Pharmaceuticals	Positive

Aurinia Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	80.73	-$351.40M	-$0.97	N/A
Aurinia Pharmaceuticals	$283.05M	7.71	$287.20M	$2.29	7.16

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 64.54%. Aurinia Pharmaceuticals has a consensus price target of $17.67, indicating a potential upside of 7.72%. Given ImmunityBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImmunityBio is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats ImmunityBio on 11 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics presently has a consensus target price of $63.00, suggesting a potential upside of 12.50%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 7.72%. Given TG Therapeutics' higher probable upside, equities research analysts plainly believe TG Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aurinia Pharmaceuticals has a net margin of 100.84% compared to TG Therapeutics' net margin of 55.22%. TG Therapeutics' return on equity of 73.49% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

In the previous week, TG Therapeutics had 7 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 7 mentions for TG Therapeutics and 0 mentions for Aurinia Pharmaceuticals. TG Therapeutics' average media sentiment score of 0.71 beat Aurinia Pharmaceuticals' score of 0.57 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TG Therapeutics	Positive
Aurinia Pharmaceuticals	Positive

TG Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.91	$447.18M	$2.74	20.44
Aurinia Pharmaceuticals	$283.05M	7.71	$287.20M	$2.29	7.16

Summary

TG Therapeutics beats Aurinia Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Aurinia Pharmaceuticals presently has a consensus price target of $17.67, indicating a potential upside of 7.72%. Vaxcyte has a consensus price target of $98.00, indicating a potential upside of 73.48%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.71	$287.20M	$2.29	7.16
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Vaxcyte's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Vaxcyte	N/A	-37.56%	-33.62%

In the previous week, Vaxcyte had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for Vaxcyte and 0 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 0.71 beat Aurinia Pharmaceuticals' score of 0.57 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurinia Pharmaceuticals	Positive
Vaxcyte	Positive

Summary

Aurinia Pharmaceuticals beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Cytokinetics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Aurinia Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

In the previous week, Cytokinetics had 9 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for Cytokinetics and 0 mentions for Aurinia Pharmaceuticals. Cytokinetics' average media sentiment score of 0.59 beat Aurinia Pharmaceuticals' score of 0.57 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurinia Pharmaceuticals	Positive
Cytokinetics	Positive

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Cytokinetics' net margin of -1,321.12%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Cytokinetics	-1,321.12%	N/A	-51.01%

Aurinia Pharmaceuticals currently has a consensus target price of $17.67, indicating a potential upside of 7.72%. Cytokinetics has a consensus target price of $103.37, indicating a potential upside of 57.07%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.71	$287.20M	$2.29	7.16
Cytokinetics	$67.67M	121.01	-$784.96M	-$7.22	N/A

Summary

Aurinia Pharmaceuticals beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Aurinia Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 7.72%. Apogee Therapeutics has a consensus target price of $126.77, suggesting a potential downside of 6.14%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Aurinia Pharmaceuticals' average media sentiment score of 0.57 beat Apogee Therapeutics' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Aurinia Pharmaceuticals	Positive
Apogee Therapeutics	Neutral

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Apogee Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Aurinia Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.71	$287.20M	$2.29	7.16
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Summary

Aurinia Pharmaceuticals beats Apogee Therapeutics on 11 of the 13 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.22B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	7.16	13.88	274.08	25.69
Price / Sales	7.71	1,343.77	638.21	78.99
Price / Cash	16.45	113.29	77.80	52.76
Price / Book	3.72	15.40	10.47	6.32
Net Income	$287.20M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-3.30%	-1.70%	-0.67%	0.17%
1 Month Performance	-1.03%	-6.17%	-3.17%	-3.27%
1 Year Performance	27.33%	30.67%	15.14%	5.58%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	3.3315 of 5 stars	$16.40 -1.6%	$17.67 +7.7%	+26.2%	$2.22B	$283.05M	7.16	128
IBRX ImmunityBio	2.3882 of 5 stars	$8.45 -0.4%	$14.20 +68.0%	+233.2%	$8.99B	$113.29M	N/A	691
TGTX TG Therapeutics	3.5368 of 5 stars	$57.16 +0.5%	$63.00 +10.2%	+57.4%	$8.71B	$616.29M	20.86	399	Analyst Upgrade
PCVX Vaxcyte	2.2599 of 5 stars	$58.92 +1.4%	$98.00 +66.3%	+70.4%	$8.65B	N/A	N/A	507
CYTK Cytokinetics	2.7697 of 5 stars	$67.59 -1.7%	$103.37 +52.9%	+35.6%	$8.56B	$88.04M	N/A	673	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. IBRX, TGTX, PCVX, CYTK, and APGE

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Summary

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Summary

How does Aurinia Pharmaceuticals compare to Cytokinetics?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. IBRX, TGTX, PCVX, CYTK, and APGE

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Which has more volatility & risk, IBRX or AUPH?

Is IBRX or AUPH more profitable?

Does the media prefer IBRX or AUPH?

Which has preferable valuation & earnings, IBRX or AUPH?

Do analysts prefer IBRX or AUPH?

Do institutionals & insiders believe in IBRX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Do institutionals and insiders hold more shares of TGTX or AUPH?

Do analysts prefer TGTX or AUPH?

Is TGTX or AUPH more profitable?

Does the media favor TGTX or AUPH?

Which has more volatility and risk, TGTX or AUPH?

Which has higher earnings and valuation, TGTX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Do analysts prefer AUPH or PCVX?

Which has better earnings & valuation, AUPH or PCVX?

Which has more risk & volatility, AUPH or PCVX?

Do institutionals & insiders believe in AUPH or PCVX?

Is AUPH or PCVX more profitable?

Does the media prefer AUPH or PCVX?

Summary

How does Aurinia Pharmaceuticals compare to Cytokinetics?

Which has more volatility & risk, AUPH or CYTK?

Does the media prefer AUPH or CYTK?

Is AUPH or CYTK more profitable?

Do analysts rate AUPH or CYTK?

Do insiders & institutionals believe in AUPH or CYTK?

Which has higher valuation & earnings, AUPH or CYTK?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Which has more volatility and risk, AUPH or APGE?

Do insiders and institutionals have more ownership in AUPH or APGE?

Do analysts rate AUPH or APGE?

Does the media favor AUPH or APGE?

Is AUPH or APGE more profitable?

Which has stronger earnings & valuation, AUPH or APGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools